



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/089,787	04/03/2002	Mohamed El-Sherbeini	20522P	1046

210 7590 12/22/2003

MERCK AND CO INC
P O BOX 2000
RAHWAY, NJ 070650907

EXAMINER

DEVI, SARVAMANGALA J N,

ART UNIT	PAPER NUMBER
----------	--------------

1645

DATE MAILED: 12/22/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary**Application No.**

10/089,787

Applicant(s)

EL-SHERBEINI ET AL.

Examiner

S. Devi, Ph.D.

Art Unit

1645

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 10 October 2003.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-16 ~~is/are~~ are pending in the application.
- 4a) Of the above claim(s) 5 and 10-16 ~~is/are~~ are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1, 3, 4 and 6-9 ~~is/are~~ are rejected.
- 7) ☒ Claim(s) 2 ~~is/are~~ objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☒ The specification is objected to by the Examiner.
- 10) ☒ The drawing(s) filed on 03 April 2002 is/are: a) ☒ accepted or b) ☐ objected to by the Examiner.
- Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. §§ 119 and 120

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.
- 13) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application) since a specific reference was included in the first sentence of the specification or in an Application Data Sheet. 37 CFR 1.78.
- a) ☐ The translation of the foreign language provisional application has been received.
- 14) ☒ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121 since a specific reference was included in the first sentence of the specification or in an Application Data Sheet. 37 CFR 1.78.

Attachment(s)

- 1) ☐ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☒ Information Disclosure Statement(s) (PTO-1449) Paper No(s) 101003.
- 4) ☐ Interview Summary (PTO-413) Paper No(s). _____.
- 5) ☐ Notice of Informal Patent Application (PTO-152)
- 6) ☒ Other: *See Continuation Sheet.*

DETAILED ACTION

Election

1) Acknowledgment is made of Applicants' election filed 10/08/03 in response to the lack of unity mailed 09/12/03. Applicants have elected invention I, claims 1-4 and 6-9 without traverse. The elected invention is directed to an isolated polynucleotide encoding a polypeptide having SEQ ID NO: 2, or that is complementary to the polynucleotide or that hybridizes with the polynucleotide, a cDNA, an expression vector and a host cell comprising the same. Because Applicants did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (M.P.E.P § 818.03(a)).

Status of Claims

2) Claims 1-16 are pending.

Claims 5 and 10-16 are withdrawn from consideration as being directed to non-elected inventions. See 37 C.F.R 1.142(b) and M.P.E.P § 821.03.

Claims 1-4 and 6-9 have been elected and are under examination. A First Action on the Merits on these claims is issued.

Sequence Listing

3) Acknowledgment is made of Applicants' submission of raw sequence listing and CRF which have been entered on 11/18/02.

Information Disclosure Statement

4) Acknowledgment is made of Applicants' Information Disclosure Statement filed 10/10/03. The information referred to therein has been considered and a signed copy is attached to this Office Action.

Priority

5) The instant application is a national stage 371 application of PCT/US00/27056, filed 09/29/2000, and claims priority to the provisional application, 60/157,580 filed 10/04/1999 in the United States.

Specification

6) The specification is objected to for the following reasons:

- (i) The specification lacks a first paragraph that provides priority information as shown

above under the section 'Priority'.

(ii) The use of the trademarks in the instant specification has been noted in this application. For example, page 8, lines 20 and 21: "Qiagen"; "Novagen"; 'Invitrogen' and 'Pharmacia'; page 10, line 28: 'Qiagen'; page 12, lines 14 and 15: 'Packard TriCarb'; and page 12, line 9: 'Triton X-100'. Although the use of trademarks is permissible in patent applications, the propriety nature of the marks should be respected and every effort made to prevent their use in any manner which might adversely affect their validity as trademarks. It is suggested that Applicants examine the whole specification and make necessary changes wherever trademark recitations appear.

Rejection(s) under 35 U.S.C. § 101

7) 35 U.S.C. § 101 states:

Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this cycle.

8) Claims 6-9 and those that depend therefrom are rejected under 35 U.S.C § 101 as being directed to a non-statutory subject matter.

Claim 6 does not sufficiently distinguish the claimed cDNA or polynucleotide over a naturally occurring cDNA or polynucleotide as it exists naturally, because the claim does not particularly point out any non-naturally occurring differences between the claimed product and the naturally occurring products. In the absence of the hand of man, the naturally occurring products are considered non-statutory subject matter. See *Diamond v. Chakrabarty*, 447 U.S. 303, 206 USPQ 193 (1980). The claim should be amended to indicate the hand of the inventor, e.g., by insertion of --An isolated ...-- if descriptive support exists for such a limitation in the instant application, as originally filed. See MPEP 2105.

Rejection(s) under 35 U.S.C § 112, Second Paragraph

9) The following is a quotation of the second paragraph of 35 U.S.C. § 112:

The specification shall conclude one or more claims particularly pointing out and distinctly claiming the subject matter which the Applicant regards as his/her invention.

10) Claims 1-4 and 6-9 are rejected under 35 U.S.C. § 112, second paragraph as being indefinite for failing to particularly point out and distinctly claim the subject matter which Applicant(s) regards as the invention.

(a) Claims 1(c) and 6(c) lack proper antecedent basis in the recitation 'a polynucleotide of (a) or (b)'. For proper antecedence, it is suggested that Applicants replace the recitation with --the polynucleotide of (a) or (b)'.

(b) Claim 1(b) and claim 6(b) are vague and indefinite in the recitation: 'complementary to the polynucleotide (a)', because it is unclear whether the complementary polynucleotide is partially complementary or fully complementary to the polynucleotide of (a).

(c) Claims 1(c) and 6(c) are vague and indefinite in the recitation "under stringent conditions". What conditions qualify as 'stringent conditions' is not clear. Does this limitation encompass low, medium or high stringency conditions?

(d) Claim 3 lacks proper antecedent basis in the recitation: 'a polynucleotide of claim 1'. For proper antecedence, it is suggested that Applicants replace the recitation with --the polynucleotide of claim 1'.

(e) Claim 7 lacks antecedence for the recitation 'cDNA in accordance with claim 6'. For proper antecedence, it is suggested that Applicants replace the recitation with --The cDNA in accordance with claim 6--.

(f) Claims 2-14 and 7-10, which depend directly or indirectly from claim 1 or claim 6, are also rejected as being indefinite, because of the vagueness or indefiniteness identified above in the base claim.

Rejection(s) under 35 U.S.A. § 102

11) The following is a quotation of the appropriate paragraphs of 35 U.S.C. § 102 that form the basis for the rejections under this section made in this Office Action:

A person shall be entitled to a patent unless –

(e) the invention was described in-

(2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that a patent shall not be deemed filed in the United States for the purposes of this subsection based on the filing of an international application filed under the treaty defined in section 351(a).

12) Claims 1, 3, 4 and 6-9 are rejected under 35 U.S.C. § 102(e)(2) as being anticipated by Rubenfield *et al.* (US 6,551,795 B1 - Applicants' IDS).

Rubenfield *et al.* disclosed an isolated cDNA or polynucleotide encoding a polypeptide having 98.7% structural identity with the instantly claimed polynucleotide of SEQ ID NO: 1, an

expression vector and a host cell comprising the same. See the attached sequence search report; 'Summary of the Invention'; columns 10-12; Exemplification; and claims. That the prior art polynucleotide with a sequence identity as high as 98.7% is complementary to the instantly claimed polynucleotide of SEQ ID NO: 1 and is expected to hybridize with the instantly claimed polynucleotide of SEQ ID NO: 1 under stringent conditions is inherent from the teachings of the prior art.

Claims 1, 3, 4 and 6-9 are anticipated by Rubenfield *et al.*

Objection

- 13) Claim 2 is objected to for being dependent from the rejected claim 1.

Remarks

- 14) Claims 1, 3, 4 and 6-9 stand rejected.

15) Papers related to this application may be submitted to Group 1600, AU 1645 by facsimile transmission. Papers should be transmitted via the PTO Fax Center located in Crystal Mall 1. The transmission of such papers by facsimile must conform with the notice published in the Official Gazette, 1096 OG 30, November 15, 1989. The CM1 facsimile center receives transmissions 24 hours a day and 7 days a week. The RightFax number for submission of before-final amendments is (703) 872-9306. The RightFax number for submission of after-final amendments is (703) 872-9307.

16) Any inquiry concerning this communication or earlier communications from the Examiner should be directed to S. Devi, Ph.D., whose telephone number is (703) 308-9347. The Examiner can normally be reached on Monday to Friday from 7.45 a.m. to 4.15 p.m. except one day each bi-week, which would be disclosed on the Examiner's voice mail system. A message may be left on the Examiner's voice mail system.

If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's supervisor, Lynette Smith, can be reached on (703) 308-3909.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-0196.

December, 2003


S. DEVI, PH.D.
PRIMARY EXAMINER

Continuation of Attachment(s) 6). Other: Sequence search report (3 pages).

SEQ ID NO. 1.

RESULT 1

US-09-252-991A-7929/c

; Sequence 7929, Application US/09252991A

; Patent No. 6551795

; GENERAL INFORMATION:

; APPLICANT: Marc J. Rubenfield et al.

; TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO PSEUDOMONAS

; TITLE OF INVENTION: AERUGINOSA FOR DIAGNOSTICS AND THERAPEUTICS

; FILE REFERENCE: 107196.136

; CURRENT APPLICATION NUMBER: US/09/252,991A

; CURRENT FILING DATE: 1999-02-18

; PRIOR APPLICATION NUMBER: US 60/074,788

; PRIOR FILING DATE: 1998-02-18

; PRIOR APPLICATION NUMBER: US 60/094,190

; PRIOR FILING DATE: 1998-07-27

; NUMBER OF SEQ ID NOS: 33142

; SEQ ID NO 7929

; LENGTH: 1170

; TYPE: DNA

; ORGANISM: Pseudomonas aeruginosa

US-09-252-991A-7929

Query Match 98.7%; Score 1068.6; DB 4; Length 1170;
Best Local Similarity 99.2%; Pred. No. 1.4e-229;
Matches 1074; Conservative 0; Mismatches 9; Indels 0; Gaps 0;

Qy	1	ATGCTCTGCTGCTGGCGGAATACCTGCAACAGTTCTACAGGGCTTCGGCGTCTTCCAG	60
Db	1167	ATGCTCTGCTGCTGGCGGAATACCTGCAACAGTTCTACAGGGCTTCGGCGTCTTCCAG	1108
Qy	61	TACCTGACCTGCGCGGCAATTCACGGTGTCTCACCGCGTGTGCTGCTGCTGCTG	120
Db	1107	TACCTGACCTGCGCGGCAATTCACGGTGTCTCACCGCGTGTGCTGCTGCTGCTG	1048
Qy	121	GGGCGCTGGATGATCCGTACCTGCGAGATCCCGAGATCGGCGAGCCGTGGCAACGAC	180
Db	1047	GGGCGCTGGATGATCCGTACCTGCGAGATCCCGAGATCGGCGAGCCGTGGCAACGAC	988
Qy	181	GGTCCGAGTGCACCTGTGCAAGAGGCGACCCCGACCATGGCGGCGCCCTGATCCTT	240
Db	987	GGTCCGAGTGCACCTGTGCAAGAGGCGACCCCGACCATGGCGGCGCCCTGATCCTT	928
Qy	241	ACCGCATAGCCATCAGCAGCTGTGTGGCGGATCTTTTCCACCGCTACGTGGGTA	300
Db	927	ACCGCATAGCCATCAGCAGCTGTGTGGCGGATCTTTTCCACCGCTACGTGGGTA	868
Qy	301	GTGCTGTGTTACCTGCTGTGCGTGCATCGGCTGGTAGACACTACCGCAGGTG	360
Db	867	GTGCTGTGTTACCTGCTGTGCGTGCATCGGCTGGTAGACACTACCGCAGGTG	808

361 ATCGAAGAACTCCGCTGGCTCGCGAGCGCTGGAGTACTTCTGCGAGTCGGTTC 420
 807 ATCGAAGAACTCCGCTGGCTCGCGAGCGCTGGAGTACTTCTGCGAGTCGGTTC 748
 421 GGCATCGCGCGCGCTGTTCTTACATGATCGCGAAGCCCGATCGAGACCACTG 480
 747 GGCATCGCGCGCGCTGTTCTTACATGATCGCGAAGCCCGATCGAGACCACTG 688
 481 ATCGTCCGATCGTGAAGAGCGTGCAGATCCAGTTCAGTTCCTTCTGTTGCTGAC 540
 687 ATCGTCCGATCGTGAAGAGCGTGCAGATCCAGTTCAGTTCCTTCTGTTGCTGAC 628
 541 TACTTCTGTCATCGCTGGCTCGAGCAATCGCGTGAACCTCACCGACGCTCGAGCGCTG 600
 627 TACTTCTGTCATCGCTGGTTCAGCAATGAGTGAACCTCACCGACGCTCGAGCGCTG 568
 601 GCGATCATCGCGAGTGAATGTTGCGCGCGCTGGCGCATCTTCTGCTACCTGTCGGGC 660
 567 GCGATCATCGCGAGTGAATGTTGCGCGCGCTGGCGCATCTTCTGCTACCTGTCGGGC 508
 661 AACGTGAATTCGCGAGTACTGCTGATTCGCAAGCTACCGGGCGCGGGAGCTGATC 720
 507 AACGTGAATTCGCGAGTACTGCTGATTCGCAAGCTACCGGGCGCGGGAGCTGATC 448
 721 GTGTTCTGCGCGCTGCTCGCGCGCTGGCGCTGGCGCTGGCGCGCTGGCGCACTC 780
 447 GTGTTCTGCGCGCTGCTCGCGCGCTGGCGCTGGCGCTGGCGCTGGCGCACTC 388
 781 GCGAGAGTCTTCATGCGCGAGTGGCGCGCTGGCGCTGGCGCGCTGGCGCGCTGGCGCACTC 840
 387 GCGAGAGTCTTCATGCGCGAGTGGCGCGCTGGCGCTGGCGCGCTGGCGCGCTGGCGCACTC 328
 841 GCGGTGATGTCGCGCGAGAGATGCTGCTGTTTCATGATGCTGGGTGTTGCTCATGAGAA 900
 327 GCGGTGATGTCGCGCGAGAGATGCTGCTGTTTCATGATGCTGGGTGTTGCTCATGAGAA 268
 901 ACCCTCTGCGTATCATCCAGTGGCTTCCTTCAAGCTGACCGGACCGCGCTCTCCGT 960
 267 ACCCTCTGCGTATCATCCAGTGGCTTCCTTCAAGCTGACCGGACCGCGCTCTCCGT 208
 961 ATGGCGCGATCCATCACCATTTCGAATGAAAGCTGGCGGACCGCGCGCTGATCGTG 1020
 207 ATGGCGCGATCCATCACCATTTCGAATGAAAGCTGGCGGACCGCGCGCTGATCGTG 148
 1021 GCTTCTGATCATCAGCGTATGCTGCTGATCGGCTCGCGACCTTGAAGCTCGGT 1080
 147 GCTTCTGATCATCAGCGTATGCTGCTGATCGGCTCGCGACCTTGAAGCTCGGT 88
 1081 TGA 1083
 87 TGA 85

RESULT 2
 US-09-252-991A-7623
 ; Sequence 7623, Application US/09252991A
 ; Patent No. 6551795
 ; GENERAL INFORMATION:
 ; APPLICANT: Marc J. Rubenfield et al.
 ; TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO PSEUDOMONAS
 ; TITLE OF INVENTION: AERUGINOSA FOR DIAGNOSTICS AND THERAPEUTICS
 ; FILE REFERENCE: 107196.136
 ; CURRENT APPLICATION NUMBER: US/09/252,991A
 ; CURRENT FILING DATE: 1999-02-18
 ; PRIOR APPLICATION NUMBER: US 60/074,788
 ; PRIOR FILING DATE: 1998-02-18
 ; PRIOR APPLICATION NUMBER: US 60/094,190
 ; PRIOR FILING DATE: 1998-07-27
 ; NUMBER OF SEQ ID NOS: 33142
 ; SEQ ID NO 7623
 ; LENGTH: 1404
 ; TYPE: DNA
 ; ORGANISM: Pseudomonas aeruginosa

US-09-252-991A-7623
 Query Match 98.7%; Score 1068.6; DB 4; Length 1404;
 Best Local Similarity 99.2%; Pred. No. 1.5e-229;
 Matches 1074; Conservative 0; Mismatch 9; Indels 0; Gaps 0;
 QY 1 ATGCTCTGCTGCTGCGCGAATACCTTGCACAGGCTTCTACAAGGCTTTCGCGCTTCTCCAG 60
 DB 322 ATGCTCTGCTGCTGCGCGAATACCTTGCACAGGCTTCTACAAGGCTTTCGCGCTTCTCCAG 381
 QY 61 TACCTGACCTGCTGCGCGCATCTTCAAGCTGCTCAACGCTGCTGCTGCTGCTGCTGCTG 120
 DB 382 TACCTGACCTGCTGCGCGCATCTTCAAGCTGCTCAACGCTGCTGCTGCTGCTGCTGCTG 441
 QY 121 GGGCCCTGATGATCCGTTCCCTTGCAGATCCCGCAGATCGCGCGCTGCGCAACGAC 180
 DB 442 GGGCCCTGATGATCCGTTCCCTTGCAGATCCCGCAGATCGCGCGCTGCGCAACGAC 501
 QY 181 GGTCCGAGTCGCGCACCTGTCGAAGAGGCGACCCCGACCATGGCGCGCGCTGATCTT 240
 DB 502 GGTCCGAGTCGCGCACCTGTCGAAGAGGCGACCCCGACCATGGCGCGCGCTGATCTT 561
 QY 241 ACCGCCATAGCCATACGACGCTGCTGCGCGGATCTTTTCAACCGCTACGCTGCTGCTG 300
 DB 562 ACCGCCATAGCCATACGACGCTGCTGCGCGGATCTTTTCAACCGCTACGCTGCTGCTG 621
 QY 301 GTGCTGCTGCTTACCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 360
 DB 622 GTGCTGCTGCTTACCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 681
 QY 361 ATCGAGAAGAACTCCGCTGGCTGGCGAGCTGGAAGTACTTCTGGCAGTCTGGTGTTC 420
 DB 682 ATCGAGAAGAACTCCGCTGGCTGGCGAGCTGGAAGTACTTCTGGCAGTCTGGTGTTC 741
 QY 421 GGCATCGCGCGCGCTGCTTCTACATGATGCTGCGAAGCCCGGATCGAGACCACTCTG 480
 DB 742 GGCATCGCGCGCGCTGCTTCTACATGATGCTGCGAAGCCCGGATCGAGACCACTCTG 801
 QY 481 ATCGTCCGATGCTGAAGAGCTGCGAGATCCAGTTCGCGCATCTTCTGCTGCTGCTGCTG 540
 DB 802 ATCGTCCGATGCTGAAGAGCTGCGAGATCCAGTTCGCGCATCTTCTGCTGCTGCTGCTG 861
 QY 541 TACTTCTGCTCATCGCTGGCTCGAGCAATGCGGTGAACCTCACCGACGCTTCTGCGCGCTG 600
 DB 862 TACTTCTGCTCATCGCTGGTTCGAGCAATGAGTGAACCTCACCGACGCTTCTGCGCGCTG 921
 QY 601 GCGATCATCGCGAGGTAATGCTGCGCGCGCTGCGGCACTTCTGCTGCTGCTGCTGCTG 660
 DB 922 GCGATCATCGCGAGGTAATGCTGCGCGCGCTGCGGCACTTCTGCTGCTGCTGCTGCTG 981
 QY 661 AACGTGAATTCGCGAGTACTGCTGATTCGCAAGCTACCGGCGCGCGCGAGCTGATC 720
 DB 982 AACGTGAATTCGCGAGTACTGCTGATTCGCAAGCTACCGGCGCGCGCGAGCTGATC 1041
 QY 721 GTGTTCTGCGCGCGCTGCTGCGCGCGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 780
 DB 1042 GTGTTCTGCGCGCGCTGCTGCGCGCGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1101
 QY 781 GCGAGGCTTTCATGCGCGAGGATCGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 840
 DB 1102 GCGAGGCTTTCATGCGCGAGGATCGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1161
 QY 841 GCGGTGATGCTGCGCGAGGATCGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 900
 DB 1162 GCGGTGATGCTGCGCGAGGATCGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 1221
 QY 901 ACCCTCTGCTGATGATCCAGTCTGCTTCTTCAAGCTGACCGGACCGCGCTGCTTCCGT 960
 DB 1222 ACCCTCTGCTGATGATCCAGTCTGCTTCTTCAAGCTGACCGGACCGCGCTGCTTCCGT 1281
 QY 961 ATGGCGCGGATCCATCACCATTTCGAAGCTGAAAGCTGCGCGGACCGCGCGCTGCTGCTG 1020
 DB 1282 ATGGCGCGGATCCATCACCATTTCGAAGCTGAAAGCTGCGCGGACCGCGCGCTGCTGCTG 1341

us-10-089-7.

Thu Dec 11 15:17:08 2003

Qy	1021	CGCTTCGGATCATCACCCTGATCTGGTGCTGATCGGCCTCGCCACCTTGAAGCTCGT	1080
Db	1342	CGCTTCGGATCATCACCCTGATCTGGTGCTGATCGGCCTCGCCACCTTGAAGCTCGT	1401
Qy	1081	TGA	1083
Db	1402	TGA	1404